Skip to content
Axcess News – Lifestyle
Author:
Herantis Pharma plc
Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096
March 5, 2026
←
Previous Page
1
2